Abstract library

55 results for "Vitali".
#3041 Resource Use in Patients with Carcinoid Syndrome: A Retrospective Analysis Using the French Health Insurance National (SNDS) Database
Introduction: About 20% of patients (pts) with neuroendocrine tumors (NET) suffer from carcinoid syndrome (CS), mainly from ileum and lung NET. Pts with CS experience symptoms such as diarrhea, flushes and cardiac complications. The diarrhea occurs in almost all pts with CS and can be truly debilitating. Therefore, on top of the tumor, the burden of the symptoms further impairs quality of life and is associated with additional costs related to symptom management and pts follow-up.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: PhD Delphine Gueguen
#2744 Immediate Adverse Effects of Peptide Receptor Radionuclide Therapy (PRRT) Administration in Patients with Neuroendocrine Tumors (NETs): A Single Institution Review
Introduction: PRRT is an effective treatment for well-differentiated NET, but immediate adverse events during or shortly after administration of the treatment are not well defined.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Christopher Wee
Authors: Wee C, Dundar A, Packard A, Kendi A T, ...
#2736 Second Primary Neoplasms in Patients with Neuroendocrine Neoplasms (NEN): DATA from a Retrospective Multicentric Study
Introduction: Patients with sporadic gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) may exhibit a higher risk of second primary tumors than the general population.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: dr Sara Massironi
#2841 Novelties in Primary and Metastatic GEP-NENs Clinical Outcome Investigation
Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) WHO classification, using strict cut-offs, should reflect their biological features. In real world, strict cut-offs not adequately segregate prognostic groups, in particular on metastasis (M).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: MD, PhD Massimo Milione
#2856 Pattern of Disease Recurrence and Treatment after Radical Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)
Introduction: The risk of recurrence after radical surgery performed for pancreatic neuroendocrine tumors (PanNET) is reported between 10 and 30%. Nowadays, no adjuvant therapy is recommended for these patients and specific treatments are offered only when recurrence occurs. Nevertheless, among the available systemic and locoregional treatments, there are no specific recommendations on which the best option could be for treating recurrent disease.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Valentina Andreasi
#2863 Introduction of Dosimetry on PRRT Practice. A Useful Tool to Detect Responders and Evaluate Treatment Safety
Introduction: PRRT is a recognized salvage option for G1-G2 GEPNET. Currently, the Italian protocol (Lutathera AIFA Guidelines) consists in four fixed-dose of 177 Lu-DOTATATE. The dosimetry has recently been recognized as an important tool to guide PRRT but is not yet part of routine practice.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD Federica Scalorbi
#77 Angiogenesis markers after hepatic artery embolization of liver metastases in patients with neuroendocrine tumors
Introduction: In the event of diffuse hepatic metastases, hepatic artery embolization (HAE) can be a successful treatment option in patients with well-differentiated neuroendocrine tumors (WNET). Although there are suggestions of activation of the angiogenesis by HAE, no information is available about the development of growth factors caused by vascular obstruction with embolization.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MSc Catharina M Korse
Authors: Korse C M, Bonfrer J M, Taal B G, ...
#109 Transarterial chemoebolization (TACE) of liver metastases derived from neuroendocrine tumors is an effective treatment only in patients with low or mediate hepatic tumor burden
Introduction: The onset of metastases in patients with neuroendocrine tumors of the gastrointestinal tract (GEP-NET) represents a negative predictor of survival and tumor-associated complications. Thereby, most of these patients develop liver metastases during their disease. Transarterial chemoembolization (TACE) has been shown before to be an effective and safe treatment of liver metastases. However, the optimal time point in treatment of liver metastases has not yet been determined, especially in patients with non-functional GEP-NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Anja Rinke
Authors: Rinke A, König A, Müller D, König U, ...
#116 Transarterial chemoembolization (TACE) of liver metastasis from pancreatic well-differentiated endocrine carcinoma
Introduction: The behavior of liver metastasis from endocrine pancreatic carcinoma is eterogeneous, and several treatments have been proposed, but no single option is ideal.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: MD Vanessa Capitanio
Authors: Capitanio V, Papa M, Zerbi A, Vitali G, ...
#132 Correlation of Ki-67 proliferative index with pathological features and outcome in pancreatic endocrine tumors
Introduction: Information on relationships between Ki-67 values and clinicopathological features in pancreatic endocrine tumors (PETs) is scant and comes mostly from a small series.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Alessandro Zerbi